What is the preferred pharmacotherapy for a patient prepared for discharge to prevent hospital readmission due to heart failure?

The preferred pharmacotherapy for a patient being discharged to prevent hospital readmission due to heart failure is the introduction of an SGLT2 inhibitor. This choice is supported by robust clinical trials that demonstrate the efficacy of SGLT2 inhibitors in reducing the risk of heart failure hospitalizations and improving overall outcomes for patients with both preserved and reduced ejection fraction. These agents not only target glucose control for diabetic patients but also have been shown to provide renal protection and improve cardiovascular outcomes, which are critical factors in heart failure management.

SGLT2 inhibitors work by promoting diuresis, reducing fluid overload, and improving cardiac hemodynamics, which can help prevent future exacerbations of heart failure that often lead to readmission. The recommendation for SGLT2 inhibitors aligns with current guidelines that emphasize the importance of these medications in heart failure treatment pathways.

Other options, while beneficial in their contexts, do not hold the same level of priority in the discharge planning to prevent readmission specifically for heart failure. Beta-blockers are important for chronic management but may not be introduced at discharge if not previously given during hospitalization. Continuous intravenous diuretics are typically not a discharge strategy as their use isn’t appropriate for outpatient settings. ACE inhibitors are also essential for long-term